All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2018-08-28T09:21:17.000Z

Tisagenlecleucel approved by the EC for the treatment of DLBCL

Aug 28, 2018
Share:

Bookmark this article

On 27 August 2018, the European Commission (EC) granted a marketing authorization for tisagenlecleucel (Kymriah) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

The US Food and Drug Administration (FDA) approved tisagenlecleucel for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma and transformed follicular lymphoma (tFL) on 01 May 2018. 

The approval was supported by data from the JULIET study. Updated results from the study were presented at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, 2018.

Key Findings

  • The ORR was consistent across subgroups = 52% (95% CI, 41%-62%); 40% complete response and 12% partial response
  • At 14 months median follow-up the median DOR was not reached
  • The 12-month relapse-free survival rate was 78.5% (95% CI, 60%-89%) among patients with a complete response and 65% (95% CI, 49%-78%) among all responders
  • For patients with a complete response, the median OS was not reached and for all patients, the OS was 11.7 months (95% CI, 6.6-not reached)

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
42 votes - 80 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox